Fox Chase Cancer Center News

PHILADELPHIA, PA (July 15, 2013)—Results from the Fox Chase study could eventually lead to the first treatment for autosomal dominant polycystic kidney disease (ADPKD)—a life-threatening and debilitating condition, and the most common inherited kidney disease.  A new compound reduces the symptoms of ADPKD in a mouse model, according to research from Fox Chase Cancer Center that will appear in the July 15, 2013 issue of the Proceedings of the National Academy of Sciences.

ROCKLEDGE, PA (July 20, 2013)—The Creative Beginnings early childhood program, which has been serving the childcare needs of Fox Chase Cancer Center employees for more than thirty years, is opening enrollment to members of the public. For the first time, community members will have the opportunity to take advantage of the high-quality program, which is accredited by the National Association for the Education of Young Children (NAEYC) and rated STAR 4 by 

CHICAGO, IL (May 29, 2013)—Monoclonal antibodies represent a promising treatment strategy for a range of cancers because they harness the immune system to specifically target and kill cancer cells while sparing normal cells, thereby reducing harmful side effects. Many monoclonal antibodies have been approved by the Food and Drug Administration (FDA), and in combination with standard chemotherapy or radiotherapy regimens, they can help to prevent tumor growth and metastasis and prolong patient survival.

CHICAGO, IL (May 29, 2013)—Patients with metastatic or recurrent forms of head and neck cancer respond better to systemic treatments if their tumors arise in association with the human papillomavirus (HPV), according to new findings to be presented by Fox Chase Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology on Sunday, June 2.

CHICAGO, IL (May 29, 2013)—A high-dose of ultrasound targeted to painful bone metastases appears to quickly bring patients relief, and with largely tolerable side effects, according to new research presented by Fox Chase Cancer Center scientists at the 49th Annual Meeting of the American Society of Clinical Oncology on Monday, June 3.

CHICAGO, IL (May 29, 2013)—Researchers from Fox Chase Cancer Center and other institutions have completed a phase II clinical trial that may help identify those patients with HPV-positive oropharyngeal cancer who do not require the full radiation dose given in a standard regimen of Intensity-Modulated Radiation Therapy (IMRT).

CHICAGO, IL (May 29, 2013)—Researchers from Fox Chase Cancer Center will present data at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1, which shows the discovery of potential biomarkers that may be used to identify patients with head and neck cancer whose tumors are unlikely to respond to treatment by the targeted therapy cetuximab—a type of monoclonal antibody. The FDA approved the drug, in combination with radiation or as a second-line drug after chemotherapy had failed, in 2006.

CHICAGO, IL (May 29, 2013)—A new study by Fox Chase Cancer Center researchers—which will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on Monday, June 3—has identified a disconnect between clinical trials that look at new treatments for metastatic pancreatic cancer and the patient population most likely to be diagnosed with the disease. Clinical trials typically enroll, and base their findings on, patients in their 50's and 60's, but the median age at diagnosis is 72.